Is CDK9 a promising target for both primary and metastatic osteosarcoma?
作者信息
Qin Jiang-Jiang
机构信息
College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China.
出版信息
EBioMedicine. 2019 Feb;40:27-28. doi: 10.1016/j.ebiom.2019.01.016. Epub 2019 Jan 14.
Abstract
摘要
相似文献
1
Is CDK9 a promising target for both primary and metastatic osteosarcoma?细胞周期蛋白依赖性激酶9（CDK9）是原发性和转移性骨肉瘤的一个有前景的靶点吗？
EBioMedicine. 2019 Feb;40:27-28. doi: 10.1016/j.ebiom.2019.01.016. Epub 2019 Jan 14.
2
Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma.周期蛋白依赖性激酶 9（CDK9）是骨肉瘤的一种新的预后标志物和治疗靶点。
EBioMedicine. 2019 Jan;39:182-193. doi: 10.1016/j.ebiom.2018.12.022. Epub 2018 Dec 20.
3
Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.骨肉瘤分子靶向治疗的当前进展与未来展望
Int J Mol Sci. 2016 Apr 6;17(4):506. doi: 10.3390/ijms17040506.
4
Wnt, osteosarcoma, and future therapy.Wnt、骨肉瘤与未来治疗
J Am Acad Orthop Surg. 2012 Jan;20(1):58-9. doi: 10.5435/JAAOS-20-01-058.
5
CDK9 inhibitors in acute myeloid leukemia.CDK9 抑制剂在急性髓系白血病中的应用。
J Exp Clin Cancer Res. 2018 Feb 23;37(1):36. doi: 10.1186/s13046-018-0704-8.
6
The anti-osteosarcoma cell activity by a mTORC1/2 dual inhibitor RES-529.mTORC1/2双重抑制剂RES-529的抗骨肉瘤细胞活性
Biochem Biophys Res Commun. 2018 Mar 4;497(2):499-505. doi: 10.1016/j.bbrc.2018.02.050. Epub 2018 Feb 9.
7
Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature.转移性骨肉瘤治疗靶点的分子改变：文献复习。
Clin Exp Metastasis. 2011 Jun;28(5):493-503. doi: 10.1007/s10585-011-9384-x. Epub 2011 Apr 2.
8
Cancer stem cells in osteosarcoma.骨肉瘤中的癌症干细胞。
Cancer Lett. 2017 Feb 1;386:189-195. doi: 10.1016/j.canlet.2016.11.019. Epub 2016 Nov 25.
9
From genomics to metabolomics: emerging metastatic biomarkers in osteosarcoma.从基因组学到代谢组学：骨肉瘤中新兴的转移性生物标志物。
Cancer Metastasis Rev. 2018 Dec;37(4):719-731. doi: 10.1007/s10555-018-9763-8.
10
Response to Pazopanib in Patients With Relapsed Osteosarcoma.复发骨肉瘤患者对帕唑帕尼的反应
J Pediatr Hematol Oncol. 2020 May;42(4):e254-e257. doi: 10.1097/MPH.0000000000001375.
引用本文的文献
1
Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.靶向小儿肿瘤学中被劫持的激酶信号通路：机遇与现状
Pharmaceutics. 2023 Feb 16;15(2):664. doi: 10.3390/pharmaceutics15020664.
2
Targeting cyclin-dependent kinase 9 in cancer therapy.靶向细胞周期蛋白依赖性激酶 9 治疗癌症。
Acta Pharmacol Sin. 2022 Jul;43(7):1633-1645. doi: 10.1038/s41401-021-00796-0. Epub 2021 Nov 22.
3
Targeting CDK9 for Anti-Cancer Therapeutics.靶向CDK9用于抗癌治疗。
Cancers (Basel). 2021 May 1;13(9):2181. doi: 10.3390/cancers13092181.
4
Identification of 9-Gene Epithelial-Mesenchymal Transition Related Signature of Osteosarcoma by Integrating Multi Cohorts.通过整合多队列鉴定骨肉瘤 9 基因上皮-间质转化相关特征。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820980769. doi: 10.1177/1533033820980769.
本文引用的文献
1
Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma.周期蛋白依赖性激酶 9（CDK9）是骨肉瘤的一种新的预后标志物和治疗靶点。
EBioMedicine. 2019 Jan;39:182-193. doi: 10.1016/j.ebiom.2018.12.022. Epub 2018 Dec 20.
2
Cyclin-dependent kinase 9 promotes cervical cancer development via AKT2/p53 pathway.周期素依赖性激酶 9 通过 AKT2/p53 通路促进宫颈癌的发展。
IUBMB Life. 2019 Mar;71(3):347-356. doi: 10.1002/iub.1983. Epub 2018 Dec 11.
3
Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer.靶向 CDK9 可重新激活癌症中被表观遗传沉默的基因。
Cell. 2018 Nov 15;175(5):1244-1258.e26. doi: 10.1016/j.cell.2018.09.051. Epub 2018 Oct 25.
4
CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy.CDK9表达在新辅助化疗后未达到病理完全缓解的乳腺癌患者中显示出作为潜在预后生物标志物的作用。
Int J Breast Cancer. 2018 Oct 14;2018:6945129. doi: 10.1155/2018/6945129. eCollection 2018.
5
CDK9 inhibitors in acute myeloid leukemia.CDK9 抑制剂在急性髓系白血病中的应用。
J Exp Clin Cancer Res. 2018 Feb 23;37(1):36. doi: 10.1186/s13046-018-0704-8.
6
Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells.抑制 CDK 介导的 Smad3 磷酸化可减少三阴性乳腺癌细胞中 Pin1-Smad3 的相互作用和侵袭性。
Cell Cycle. 2017 Aug 3;16(15):1453-1464. doi: 10.1080/15384101.2017.1338988. Epub 2017 Jul 5.
7
Review of Osteosarcoma and Current Management.骨肉瘤综述与当前治疗方法
Rheumatol Ther. 2016 Dec;3(2):221-243. doi: 10.1007/s40744-016-0046-y. Epub 2016 Oct 19.
8
Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors.靶向人类癌症中的细胞周期蛋白依赖性激酶：从小分子到肽抑制剂
Cancers (Basel). 2015 Jan 23;7(1):179-237. doi: 10.3390/cancers7010179.
9
Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.使用新型特异性抑制剂对细胞周期蛋白依赖性激酶CDK9的分子和细胞功能进行表征。
Br J Pharmacol. 2014 Jan;171(1):55-68. doi: 10.1111/bph.12408.
10
Cyclin-dependent kinase 9 is required for tumor necrosis factor-alpha-stimulated matrix metalloproteinase-9 expression in human lung adenocarcinoma cells.细胞周期蛋白依赖性激酶9是肿瘤坏死因子-α刺激人肺腺癌细胞中基质金属蛋白酶-9表达所必需的。
J Biol Chem. 2005 Jan 14;280(2):1103-11. doi: 10.1074/jbc.M406293200. Epub 2004 Nov 4.
Zotero 插件